An activist invester has taken interest in pharma giant Pfizer, which despite becoming a household name during the pandemic ...

Shares of GSK PLC GSK rose 1.40% to £14.80 Monday, on what proved to be an all-around favorable trading session for the stock ...

Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...

Pfizer (NYSE:PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (NYSE:GSK) patents for its RSV ...

Millions of people who bought DNA tests from genetic testing service 23andme have been urged to delete their personal data ...

Mpox – formerly known as monkeypox – is rapidly spreading in several African countries, prompting the World Health ...

The company is committing to make at least 2 million doses of its long-acting PrEP therapy available in low- and middle-income countries next year and in 2026.

GSK, Sanofi and CSL Ltd have secured $72 million from the US government to ramp up production of bird flu vaccines, Reuters ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...

The mRNA-based supplier of vaccines profited from Covid-19 vaccine sales. As the years passed, Covid evolved. The weaker ...

The idea is that if you move your focus to attracting people, you’ll ultimately attract the companies: If you build it (the ...